To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for Vaccines and Gene Therapies Using PER.C6® Cell Line Technology
Read time: Less than a minute
Eden Biodesign's custom-designed and licensed cGMP manufacturing facility offers fully segregated viral production at a range of scales, using a variety of production technologies and processes, including a platform approach for the production of adenoviruses in stirred tank suspension culture.
Crucell’s comprehensive package of technology and know-how relating to the human PER.C6® cell line provides a safe and cost-effective manufacturing system for high-yield, large-scale production of vaccines, recombinant proteins and gene therapy products.
The addition of Eden Biodesign to Crucell’s preferred vendor network comes about, in part, as a result of the parties having recently worked together to assist a third party company with extremely rapid and cost-effective progression of an adenoviral product into human clinical trials.
Commenting on the agreement, Crawford Brown, Ph.D., CEO of Eden Biodesign said, “We are delighted to strengthen our relationship with Crucell and to be able to offer Eden Biodesign’s services to Crucell’s PER.C6® licensees. We have demonstrated that the combination of Crucell’s proven and valuable technology and Eden Biodesign’s expertise in vaccine and gene therapy development and manufacturing delivers tremendous value to our customers by accelerating progression of products into and through clinical development, while maintaining the ability to scale-up production and achieve a highly attractive cost-of-goods.”
Crucell’s comprehensive package of technology and know-how relating to the human PER.C6® cell line provides a safe and cost-effective manufacturing system for high-yield, large-scale production of vaccines, recombinant proteins and gene therapy products.
The addition of Eden Biodesign to Crucell’s preferred vendor network comes about, in part, as a result of the parties having recently worked together to assist a third party company with extremely rapid and cost-effective progression of an adenoviral product into human clinical trials.
Commenting on the agreement, Crawford Brown, Ph.D., CEO of Eden Biodesign said, “We are delighted to strengthen our relationship with Crucell and to be able to offer Eden Biodesign’s services to Crucell’s PER.C6® licensees. We have demonstrated that the combination of Crucell’s proven and valuable technology and Eden Biodesign’s expertise in vaccine and gene therapy development and manufacturing delivers tremendous value to our customers by accelerating progression of products into and through clinical development, while maintaining the ability to scale-up production and achieve a highly attractive cost-of-goods.”
